Gottlieb criticizes sponsors’ ‘continued reluctance’ to rethink clinical trials

Outgoing FDA Commissioner Scott Gottlieb, M.D., has criticized the “continued reluctance” of sponsors and CROs to adopt innovative approaches to clinical trials. Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

READ  Making Innovative Drugs Available Globally

Categories: Industry

Tagged as: , , , ,

Leave a Reply